Johnson & Johnson (NYSE:JNJ) Stock Rating Reaffirmed by Cantor Fitzgerald

Cantor Fitzgerald reaffirmed their overweight rating on shares of Johnson & Johnson (NYSE:JNJ) in a report published on Monday, Benzinga reports. They currently have a $215.00 price objective on the stock.

Several other research analysts have also recently weighed in on JNJ. Morgan Stanley decreased their price objective on shares of Johnson & Johnson from $168.00 to $167.00 and set an equal weight rating for the company in a report on Wednesday, April 17th. HSBC upgraded Johnson & Johnson from a hold rating to a buy rating and raised their price target for the stock from $169.00 to $170.00 in a research note on Thursday, April 18th. The Goldman Sachs Group assumed coverage on Johnson & Johnson in a research report on Thursday, May 30th. They set a neutral rating and a $160.00 price objective for the company. Royal Bank of Canada restated an outperform rating and set a $175.00 price target on shares of Johnson & Johnson in a research note on Monday, June 17th. Finally, StockNews.com upgraded shares of Johnson & Johnson from a buy rating to a strong-buy rating in a research note on Sunday. Eight research analysts have rated the stock with a hold rating, five have given a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of Moderate Buy and a consensus target price of $174.07.

Johnson & Johnson Price Performance

Shares of NYSE JNJ opened at $145.62 on Monday. The company has a market capitalization of $350.46 billion, a PE ratio of 9.03, a PEG ratio of 2.43 and a beta of 0.52. The company has a quick ratio of 0.94, a current ratio of 1.17 and a debt-to-equity ratio of 0.36. The stock’s 50 day moving average price is $148.02 and its 200-day moving average price is $153.91. Johnson & Johnson has a twelve month low of $143.13 and a twelve month high of $175.97.

Johnson & Johnson (NYSE:JNJ) last released its earnings results on Tuesday, April 16th. The company reported $2.71 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.64 by $0.07. The business had revenue of $21.38 billion during the quarter, compared to the consensus estimate of $21.39 billion. Johnson & Johnson had a return on equity of 36.70% and a net margin of 45.26%. The business’s revenue for the quarter was up 2.3% on a year-over-year basis. During the same period last year, the business posted $2.68 earnings per share. On average, equities analysts anticipate that Johnson & Johnson will post 10.62 EPS for the current year.

Johnson & Johnson Increases Dividend

The firm also recently declared a quarterly dividend, which was paid on Tuesday, June 4th. Stockholders of record on Tuesday, May 21st were issued a dividend of $1.24 per share. The ex-dividend date of this dividend was Monday, May 20th. This is a boost from Johnson & Johnson’s previous quarterly dividend of $1.19. This represents a $4.96 dividend on an annualized basis and a dividend yield of 3.41%. Johnson & Johnson’s dividend payout ratio is currently 30.92%.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the stock. Christopher J. Hasenberg Inc acquired a new position in shares of Johnson & Johnson during the 1st quarter worth about $31,000. Keener Financial Planning LLC purchased a new position in Johnson & Johnson in the fourth quarter valued at approximately $40,000. WFA Asset Management Corp raised its holdings in Johnson & Johnson by 61.4% during the fourth quarter. WFA Asset Management Corp now owns 255 shares of the company’s stock worth $40,000 after purchasing an additional 97 shares in the last quarter. Vermillion & White Wealth Management Group LLC acquired a new position in shares of Johnson & Johnson in the 4th quarter valued at $44,000. Finally, Disciplined Equity Management Inc. acquired a new stake in Johnson & Johnson during the 4th quarter worth $45,000. 69.55% of the stock is owned by institutional investors and hedge funds.

About Johnson & Johnson

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.